表紙
市場調查報告書
商品編碼
1024222

敗血症:現在及今後的市場機會,流行病學調查,市場動態,開發平台分析,r-NPV分析

Sepsis - Current & Forecasted Market Opportunities, Epidemiological Studies, Market Dynamics, Pipeline Analytics and r-NPV Analysis

出版日期: | 出版商: GervanoRA Data Services LLP | 英文 239 Pages | 商品交期: 3-5個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

本報告提供敗血症的相關調查,提供流行病學研究,市場規模和預測,活用KOL洞察的新加入企業價格策略,風險調整淨現值(RNPV)分析,開發管線洞察和基準概述,競爭情形,未滿足需求和機會等資訊。

目錄

第1章 簡介

第2章 摘要整理

第3章 疾病的概要與流行病學調查

第4章 敗血症的市場銷售額:現在·預測(2020-2030)

第5章 開發平台(管線)的洞察和基準預測

第6章 敗血症競爭空間的交易活動

第7章 敗血症管線藥物的專利比較分析

第8章 風險調整淨現值(R-NPV)分析

第9章 競爭機會的評估

目錄
Product Code: GERPH1532

GervanoRA's pipeline analysis and opportunity assessment report "Sepsis - Current & Forecasted Market Opportunities, Epidemiological Studies, Market Dynamics, Pipeline Analytics and r-NPV Analysis" analysed and assessed Sepsis pipeline molecules for the opportunities in the competitive space by covering all the pipeline molecules in different stages of development and all the companies which are actively involved in Sepsis drugs industry.

The report has been divided into segments like Disease Overview, Market Overview, Pipeline Analytics to provide in depth insights about the market dynamics and ongoing R&D in the Sepsis area. The report provides detailed insights about all the pipeline molecules in different stages of development and all the companies which are actively involved in Sepsis drugs industry. To provide systematic pipeline analytics, we have segregated total pipeline molecules into different segments like Pipeline Analytics by Stage of development, Pipeline Analytics by Route of Administration, Pipeline Analytics by Geography, Pipeline Analytics by Mechanism of Action, Pipeline Analytics by Drug Class, Pipeline Analytics by Molecule Type, Pipeline Analytics by Target and Pipeline Analytics by Company Type.

The report delivers an in-depth understanding of the Sepsis historical and forecasted epidemiology based market trends Worldwide, the United States, EU9 (Poland, Russia, Switzerland, Sweden, Italy, Germany, Austria, France, and United Kingdom) and China. A detailed analytics on the Current Sepsis Market (2020) and the Forecasted Sepsis Market until the year 2030 for the regions have been provided.

Growth opportunities in the report have been provided by performing a competitive and comparative analysis on the Emerging companies in the domain based on In-Licensing opportunities, Out-Licensing opportunities, Corporate Partnering opportunities and funding opportunities. The report even aimed to conduct the Risk-Adjusted Net Present Value (RNPV) Analysis with its Excel based r-NPV analysis model to help companies in licensing negotiations, technology valuations and pipeline asset valuation and establishing the value for licensing deal. It also aims to provide the sales potential of the drugs along with the new drugs pricing and pricing strategies.

Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on:

  • Epidemiological Studies - Historical Trends and Probabilistic Epidemiology Forecast
  • Epidemiology Based Market Estimations - Current Market Value and Market Forecast
  • Plotting of the Anticipated Market Share for the New Entrants
  • Pricing Strategies of New Entrants Supported Through KOL Insights
  • Risk-Adjusted Net Present Value (RNPV) Analysis
  • Comparative Pipeline Insights and Benchmarking Snapshots by HSD, Geography, RoA, Drug Class, MoA, Molecule Target, Molecule Type
  • Unmet Needs and Opportunities
  • Comparative Patent Analytics of Sepsis Pipeline Drugs
  • Competitive Opportunity Assessments of the Active Players in the Sepsis Therapeutic Space by Partnering, Licensing and Funding Opportunities
  • Deals Activities of Sepsis Therapeutic Space

Report helps clients to refine the commercial opportunities from the existing treatment armamentarium to pipeline assets, deals, and deal comparables. Even it helps in identifying the most relevant actors in the field for partnering deals.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: DISEASE OVERVIEW AND EPIDEMIOLOGICAL STUDIES

CHAPTER 4: SEPSIS CURRENT MARKET VALUE AND FORECAST 2020 - 2030

CHAPTER 5: PIPELINE INSIGHTS AND BENCHMARKING OUTLOOK

CHAPTER 6: DEALS ACTIVITIES OF SEPSIS COMPETITIVE SPACE

CHAPTER 7: COMPARATIVE PATENT ANALYTICS OF SEPSIS PIPELINE DRUGS

CHAPTER 8: RISK-ADJUSTED NET PRESENT VALUE (R-NPV) ANALYSIS

CHAPTER 9: COMPETITIVE OPPORTUNITY ASSESSMENTS

LIST OF TABLES (COMPLETE LIST CAN BE FOUND IN FULL LENGTH REPORT)

  • TABLE 01: SEPSIS REPORT HIGHLIGHTS IN NUMERICALS
  • TABLE 02: CLASSIFICATION OF SEPSIS
  • TABLE 03: SEPSIS APPROVED DRUGS
  • TABLE 04: INCIDENT RATES OF HOSPITAL TREATED SEVERE SEPSIS ACROSS EUROPEAN REGIONS
  • TABLE 05: FINANCING DEALS IN SEPSIS THERAPEUTIC AREA
  • TABLE 06: COLLABORATION DEALS IN SEPSIS THERAPEUTIC AREA
  • TABLE 07: LICENSING DEALS IN SEPSIS THERAPEUTIC AREA
  • TABLE 08: MERGER AND ACQUISITION DEALS IN SEPSIS THERAPEUTIC AREA
  • TABLE 09: SEPSIS PIPELINE DRUGS BY STAGE OF DEVELOPMENT
  • TABLE 10: SEPSIS PHASE III PIPELINE MOLECULES
  • TABLE 11: SEPSIS PHASE II PIPELINE MOLECULES
  • TABLE 12: SEPSIS PHASE I PIPELINE MOLECULES
  • TABLE 13: SEPSIS PRECLINICAL PIPELINE MOLECULES
  • TABLE 14: SEPSIS EARLY R&D PIPELINE MOLECULES
  • TABLE 15: INACTIVE AND DISCONTINUED MOLECULES IN SEPSIS
  • TABLE 16: LIST OF PIPELINE MOLECULES WITH PARENTERAL ROUTE OF ADMINISTRATION
  • TABLE 17: LIST OF PIPELINE MOLECULES WITH ORAL ROUTE OF ADMINISTRATION
  • TABLE 18: ANTI-INFLAMMATORY DRUGS UNDER DEVELOPMENT
  • TABLE 19: IMMUNOMODULATORY DRUGS UNDER DEVELOPMENT
  • TABLE 20: CELL-BASED THERAPIES UNDER DEVELOPMENT
  • TABLE 21: PEPTIDE-BASED THERAPIES UNDER DEVELOPMENT
  • TABLE 22: PROTEIN ACTIVATORS AND INHIBITORS UNDER DEVELOPMENT
  • TABLE 23: LIST OF SEPSIS PIPELINE MOLECULES WITH THEIR MECHANISM OF ACTIONS
  • TABLE 24: LIST OF COMPANIES DEVELOPING BIOLOGIC DRUGS
  • TABLE 25: LIST OF PIPELINE MOLECULES WITH THE MOLECULE TARGET

LIST OF FIGURES (COMPLETE LIST CAN BE FOUND IN FULL LENGTH REPORT)

  • FIGURE 01: KEY EVENTS IN THE SEPSIS COMPETITIVE SPACE
  • FIGURE 02: SEPSIS TOTAL MARKET SHARE
  • FIGURE 03: COMPARISON OF SEPSIS MARKET SHARE, 2023 VERSUS 2027
  • FIGURE 04: ZEMPIA EXPECTED MARKET SHARE IN 2023
  • FIGURE 05: COMPARISON OF EXPECTED PEAK SALES OF ZEMPIA, ART-123 AND REXIS
  • FIGURE 06: ESTIMATED MARKET SHARE (%) OVERVIEW IN 2023
  • FIGURE 07: ESTIMATED MARKET SHARE (%) OVERVIEW IN 2024
  • FIGURE 08: ESTIMATED MARKET SHARE (%) OVERVIEW IN 2025
  • FIGURE 09: ESTIMATED MARKET SHARE (%) OVERVIEW IN 2027
  • FIGURE 10: SEPSIS DRUG PIPELINE SCENARIO, COMPANY TYPE AND DRUG CANDIDATES WRT HSD
  • FIGURE 11: SEPSIS DEAL ANALYTICS BY DEAL TYPE
  • FIGURE 12: SEPSIS DEAL ANALYTICS BY DEAL FREQUENCY
  • FIGURE 13: DEAL TYPE BREAKDOWN FOR THE YEAR OF 2020
  • FIGURE 14: DEALS ANALYTICS BY ACTIVE PLAYERS IN SEPSIS MARKET
  • FIGURE 15: BREAKDOWN OF PATENTS FILED ACROSS THE GLOBE FOR SEPSIS TREATMENT
  • FIGURE 16: PIPELINE MOLECULES - CLINICAL VS PRECLINICAL & EARLY R&D
  • FIGURE 17: TOTAL PIPELINE MOLECULES VS STAGE OF DEVELOPMENT
  • FIGURE 18: SCHEMATIC REPRESENTATION OF SEPSIS WORLDWIDE ANTICIPATED DRUG APPROVALS
  • FIGURE 19: GRAPHICAL REPRESENTATION OF SEPSIS PIPELINE DRUGS FOR APPROVAL REGIONS & HSD
  • FIGURE 20: SEPSIS DRUGS PIPELINE ANALYTICS BY ROA
  • FIGURE 21: SEPSIS DRUGS PIPELINE ANALYTICS BY PARENTERAL ROA
  • FIGURE 22: PARENTERAL DRUGS PIPELINE ANALYTICS BY STAGE OF DEVELOPMENT
  • FIGURE 23: TOTAL PIPELINE MOLECULES V/S DRUG CLASSES
  • FIGURE 24: LIST OF COMPANIES WITH RESPECT TO THE DRUG CLASSES
  • FIGURE 25: PIPELINE DRUG CLASS ANALYTICS BY STAGE OF DEVELOPMENT